Alnylam Pharmaceuticals, Inc.

ALNY

$264.50

-1.08%

N/A-$2.90

Healthcare

Biotechnology

NASDAQ

Negociación activa

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid ...

Métricas clave de ALNY

Instantánea

Último / TTM · 6 periodos

Capitalización

$35.39B

ROCE

24.7%

EV / EBITDA

30.38x

+10.4% YoY

Rendimiento FCF

1.5%

+0.6% YoY

Ciclo de conversión de efectivo

65.3d

Ratio corriente

3.05

Resumen rápido

TTM —

Positive CCC

Métricas clave

Último / TTM · 6 periodos

Tendencia de valoración

Tendencia de valoración table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$20.09B	$28.92B	$23.91B	$30.04B	$52.09B	$35.39B
Enterprise ValueCompany value including debt and cash adjustments.	$20.26B	$29.37B	$24.40B	$30.37B	$51.71B	$34.95B
EV / SalesHow many dollars investors pay per dollar of sales.	24.00x	28.31x	13.35x	13.51x	13.92x	7.28x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-30.63x	-31.70x	-94.49x	-169.79x	81.90x	30.38x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	-0.27	-0.49	-1.91	-1.84	-0.60	-0.38

Retornos + indicador ROCE

ROCE más reciente

24.7%

Prev year 14.3%

Retornos + indicador ROCE table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-145.0%	714.9%	199.5%	-414.6%	39.8%	93.6%
ROAProfit generated from total assets.	-23.4%	-31.9%	-11.5%	-6.6%	6.3%	14.5%
ROICReturn generated on invested operating capital.	-24.9%	-36.6%	-11.6%	-6.2%	17.0%	29.9%
ROCEOperating return on long-term capital used.	-24.0%	-28.3%	-9.9%	-5.8%	14.3%	24.7%
Earnings YieldEarnings as a percentage of market value.	-4.2%	-3.9%	-1.8%	-0.9%	0.6%	2.3%

Calidad del flujo de caja

Calidad del flujo de caja table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-574.93M	$-456.79M	$165.05M	$61.97M	$710.66M	$883.77M
FCFECash flow available to equity holders after debt flows.	$-218.06M	$-359.33M	$41.95M	$-42.59M	$-81.56M	$-10.11M
FCF YieldFree cash flow divided by market capitalization.	-3.6%	-2.1%	0.2%	-0.1%	0.9%	1.5%
Income QualityHow well accounting earnings are backed by cash flow.	0.75	0.48	-0.24	0.03	1.67	0.79
Capex / OCFShare of operating cash flow spent on capital expenditures.	-11.9%	-13.3%	59.7%	-412.4%	11.2%	14.5%

Eficiencia operativa

Eficiencia operativa table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	85.8d	83.7d	65.4d	65.8d	76.4d	69.3d
DIOAverage days inventory stays before being sold.	224.9d	278.8d	104.8d	88.6d	44.6d	36.4d
DPOAverage days the company takes to pay suppliers.	191.2d	212.1d	65.3d	99.8d	62.4d	40.5d
Operating CycleTime from buying inventory to collecting receivables.	310.8d	362.6d	170.3d	154.4d	121.0d	105.7d
Cash Conversion CycleNet days cash is tied in operations.	119.5d	150.5d	105.0d	54.6d	58.6d	65.3d

Instantánea

Último / TTM: —

Capitalización

$35.39B

ROE

93.6%

Rendimiento FCF

1.5%

Ratio corriente

3.05

Cadena de suministro de ALNY

Upstream / Downstream / Proxy

Upstream

Agilent TechnologiesNYSE:AGenevant SciencesPeptiDream Inc.TSE:4587Blackstone Life SciencesMax Planck InnovationIonis Pharmaceuticals (formerly Isis)NASDAQ:IONSInceptive NucleicsArbutus BiopharmaNASDAQ:ABUSNucleoside Phosphoramidite Manufacturers (multiple)Lipid Component Suppliers for LNPs

Downstream

Novartis AGNYSE:NVSRoche Holding AGSWX:ROGSanofiEURONEXT:SANRegeneron PharmaceuticalsNASDAQ:REGNMedison PharmaAgios PharmaceuticalsNASDAQ:AGIO Vir BiotechnologyNASDAQ:VIROrsini Specialty PharmacyArrowhead PharmaceuticalsNASDAQ:ARWRScenic Biotech

Empresas proxy

Ionis PharmaceuticalsNASDAQ:IONS Regulus TherapeuticsNASDAQ:RGLS Arrowhead PharmaceuticalsNASDAQ:ARWR Arbutus BiopharmaNASDAQ:ABUS

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal